DIRS.INFO The most relevant business & tech news

☆ As Covid-testing business drops, Abbott searches for new line of business with consumer wearables
▼ + stars: | 2023-10-10 | by ( Ashley Capoot | ) www.cnbc.com time to read: +3 min

Abbott Laboratories CEO Robert Ford took the stage at the HLTH conference in Las Vegas on Tuesday to discuss the company's expansion into a new market: consumer wearables. For instance, Abbott produces a continuous glucose monitor (CGM) called FreeStyle Libre that patients can use to manage their diabetes. Abbott's most recent model, the FreeStyle Libre 3, can measure glucose levels in real time for up to 14 days. FreeStyle Libre alone generated more than $1.3 billion in sales for Abbott during its second quarter, according to the company's earnings report. "We always believed that we could take this platform that we developed for diabetes and expand it beyond diabetes," Ford said.

Persons: Robert B, Ford, Robert Ford, Abbott, Covid, Margaret Kaczor Andrew, William Blair, CNBC's Erin Black, Lingo Organizations: Abbott, Libre, wearables Locations: Vegas, Las Vegas , Nevada, Las Vegas, U.S

☆ US FDA warns 3 baby formula makers to correct manufacturing process controls
▼ + stars: | 2023-08-30 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. The FDA pulled up these companies for failing to establish processes to ensure infant formula does not become contaminated during manufacturing. The recalls were meant to remove products potentially contaminated with the bacteria cronobacter sakazakii, the FDA added. "The agency... believes that the recalls were effective in removing the potentially contaminated batches of product from the market," the FDA said. Infant formula manufacturing is under greater scrutiny following the shortage of the product last year due to a shutdown of Abbott Laboratories' (ABT.N) unit in Michigan.

Persons: Andrew Kelly, Benckiser, Mead Johnson, Perrigo, ByHeart, Leroy Leo, Krishna Chandra Organizations: Food and Drug Administration, FDA, REUTERS, U.S . Food, Drug Administration, ByHeart Inc, Mead Johnson Nutrition, Abbott Laboratories, Thomson Locations: White Oak , Maryland, U.S, PRGO.N, Wisconsin, Michigan, Bengaluru

☆ 30 dividend-paying stocks in solid sectors with upside outside the AI hype, according to a 30-year fund manager
▼ + stars: | 2023-08-27 | by ( Laila Maidan | ) www.businessinsider.com time to read: +6 min

Similar companies within the healthcare sector in his portfolio include Abbott Laboratories (ABT), which pays out a 1.95% dividend yield. Additionally, it offers a 2.35% dividend yield. Within the defense sector, he also likes Lockheed Martin (LMT), which pays a dividend yield of 2.64%. It pays out a 2.19% dividend yield plus a profit and losses payout at the end of the year. It has a 2.85% dividend yield and has increased its payout by about 8 to 10% a year, he said.

Persons: Max Wasserman, He's, Wasserman, overvalued, That's, Johnson, There's, Lockheed Martin Organizations: Miramar Capital LLC, Nasdaq, Broadcom, Microsoft, Company, NAPA Auto, Parts, Abbott Laboratories, Merck & Co, Dynamics, Group, PepsiCo Locations: Northbrook , Illinois, NAPA

☆ Wall St Week Ahead Historically stormy month of September may test US stock rally
▼ + stars: | 2023-08-25 | by ( David Randall | ) www.reuters.com time to read: +4 min

The Wall Street entrance to the New York Stock Exchange (NYSE) is seen in New York City, U.S., November 15, 2022. In Septembers since 1945, the S&P 500 has declined an average of 0.7%, the worst performance of any month, according to CFRA. Of course, bullish stock investors have largely been rewarded for looking past potential pitfalls this year. "The correction started on the first day of the month, and now it has corrected the conditions that made it vulnerable," Hayes said. Reporting by David Randall; Additional reporting by Lewis Krauskopf; Editing by Ira Iosebashvili and David GregorioOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Jack Janasiewicz, Janasiewicz, Jerome Powell, Sandy Villere, Goldman Sachs, Tim Hayes, Ned Davis, Hayes, David Randall, Lewis Krauskopf, Ira Iosebashvili, David Gregorio Our Organizations: New York Stock Exchange, REUTERS, Reserve, Natixis, Solutions, U.S, Villere, Pfizer, Abbott Laboratories, Investors, Republicans, U.S . House, Goldman, Federal, Ned, Ned Davis Research, Thomson Locations: New York City, U.S, Jackson

Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. Medtronic, which makes pacemakers, catheters and other tools used in heart and gastrointestinal surgeries, joins rivals, including Abbott Laboratories (ABT.N), Stryker (SYK.N) and Boston Scientific (BSX.N), on benefiting from a rise in non-urgent surgeries. CEO Geoff Martha said trends pointed to a recovery in surgical volumes as some procedures returned to stronger than pre-pandemic levels. Whereas, revenue from its medical surgical unit rose 5.5% to $2.04 billion. Medtronic also said that it was expecting to split its patient monitoring and respiratory interventions businesses in the first half of fiscal 2025.

Persons: Dado Ruvic, Stryker, Geoff Martha, It's, Martha, Edward Jones, John Boylan, Medtronic, Bhanvi Satija, Christy Santhosh, Shweta Agarwal Organizations: REUTERS, Abbott, Abbott Laboratories, Boston, Thomson Locations: Dublin, Bengaluru

☆ Medtronic raises forecast as demand for heart devices powers upbeat results
▼ + stars: | 2023-08-22 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsAug 22 (Reuters) - Medtronic (MDT.N) on Tuesday raised its annual profit forecast, after beating first-quarter estimates on higher demand for its medical devices used in heart and gastrointestinal surgeries. A recovery in non-urgent procedures and easing staffing shortages following a decline in COVID-19 cases has boosted the demand for medical devices. Sales at Medtronic's heart devices unit, its biggest revenue driver, increased 5.5% to $2.85 billion for the first quarter, above analysts' estimates of $2.78 billion. Revenue for the quarter rose 4.5% to $7.70 billion, topping analysts' average estimate of $7.57 billion. Its adjusted profit of $1.20 per share for the quarter ended July 28 beat estimates of $1.11 per share.

Persons: Dado Ruvic, Medtronic, Stryker, Bhanvi Satija, Christy Santhosh, Shweta Agarwal Organizations: REUTERS, Abbott Laboratories, Boston, Revenue, Thomson Locations: COVID, Dublin, Bengaluru

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound
▼ + stars: | 2023-08-01 | by ( ) www.reuters.com time to read: +1 min

Aug 1 (Reuters) - Zimmer Biomet Holdings Inc (ZBH.N) on Tuesday raised its full-year profit forecast, anticipating demand to hold up for its medical devices following a rebound in knee and hip replacement procedures. Abbott Laboratories (ABT.N) attributed its strong quarter to hospitals addressing bottlenecks from the pandemic while Johnson & Johnson (JNJ.N) said it expected to top profit estimates with surgeries bouncing back. The company now expects full-year profit of $7.47 to $7.57 per share, compared with its previous forecast of $7.40 to $7.50. The Indiana-based company's second-quarter revenue rose nearly 5% to $1.87 billion, beating analysts' estimates of $1.83 billion. Zimmer also expects reported revenue to grow between 6.5% and 7% this year, compared to its prior forecast of between 5% and 6%.

Persons: Zimmer, Johnson, Jeff Johnson, Mariam Sunny, Sriraj Organizations: Zimmer Biomet Holdings, Abbott Laboratories, Baird Equity, Thomson Locations: Indiana, Bengaluru

☆ This ETF is the best way to play a 'goldilocks' health-care sector, Bank of America says
▼ + stars: | 2023-07-28 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +2 min

A health-care fund with a strong track record could be in a sweet spot for investors who are looking to take some risk off the table, according to Bank of America. "Since 2006, HCES has been a 'goldilocks' trade for investors looking for high-beta healthcare exposure without extreme volatility," the note said. The firm's top-rated ETF in the space is the iShares U.S. Medical Devices ETF (IHI) , which helps investors avoid the volatile biotech stocks found in broader health-care sector funds. IHI 5Y mountain The IHI has averaged a total return of more than 10% over the past five years. In our view, the trade is far less crowded than broad healthcare for investors looking for defensive exposure," Woodard said.

Persons: Jared Woodard, HCES, Woodard, — CNBC's Michael Bloom Organizations: Bank of America . Investment, Medical Devices, Fisher, Abbott Laboratories, Bank of America Locations: U.S

☆ GE HealthCare raises 2023 profit forecast as supply chain woes ease
▼ + stars: | 2023-07-25 | by ( ) www.reuters.com time to read: +2 min

July 25 (Reuters) - GE HealthCare Technologies Inc (GEHC.O) raised its annual profit forecast on Tuesday, after beating quarterly earnings estimates due to easing supply chain issues that had largely impacted electronic components during the pandemic. Johnson & Johnson (JNJ.N) and Abbott Laboratories (ABT.N), which make medical devices like heart stents and implants, surpassed quarterly profit estimates last week as patients underwent their delayed procedures. GE HealthCare on Tuesday reported total quarterly sales of $4.8 billion, in line with analysts' estimates. Of this, $2.6 billion came from sales of imaging devices such as magnetic resonance imaging (MRI) and $839 million from ultrasound devices. The healthcare equipment firm operates four medical device businesses - imaging and ultrasound devices, patient care solutions and pharmaceutical diagnostics - with imaging being the largest.

Persons: Johnson, Khushi, Shailesh Organizations: GE HealthCare Technologies Inc, GE, Johnson, Abbott Laboratories, GE HealthCare, General Electric, Thomson Locations: Bengaluru

☆ Morning Bid: Tesla, Netflix underwhelm
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +4 min

[1/2] A Tesla logo is seen outside a showroom of the carmaker in Beijing, China May 31, 2023. REUTERS/Thomas Peter/File PhotoA look at the day ahead in U.S. and global markets from Mike DolanAn overdue cold shower? July 20 (Reuters) - The first of the supercharged Big Tech firms to report in this earnings season - Tesla and Netflix - seemed to underwhelm markets overnight, cutting across the enthusiastic reception for big banks and knocking back bulled-up Wall St from 2023 highs. Although electric car giant Tesla (TSLA.O) comfortably beat second quarter profit forecasts, markets seized on plans for continued price discounting and squeezed margins as a reason to drag its shares down almost 4% in overnight trading. In the fixed income world, Treasury yields crept back higher ahead of next week's Federal Reserve meeting.

Persons: Thomas Peter, Mike Dolan, Dow Jones, McLennan, Philip Morris, WR, DR Horton, Janet Yellen, John Organizations: REUTERS, Big Tech, Netflix, Overseas, Citizens, US Bancorp, Energy, Healthcare, Abbott Laboratories, Johnson, Blackstone, Truist Financial, American Airlines, Marsh, WR Berkley, CSX, Philadelphia Federal Reserve, Treasury, Reuters Graphics Housing, Reuters Graphics Reuters, Thomson, Reuters Locations: Beijing, China, U.S, Russia, Britain, Newmont, Freeport, McMoRan, DR, Philadelphia, Turkey, South Africa, Vietnam

Johnson & Johnson Covid-19 vaccines are seen on a table on May 7, 2021 in Los Angeles, California. Johnson & Johnson —The stock jumped 6%, lifting the 30-stock Dow Jones Industrial Average, after the the health care posted second-quarter revenue and adjusted earnings that topped Wall Street's expectations. Johnson & Johnson also lifted its full-year guidance as sales from the company's medtech business jumped. Discover Financial Services — Shares tumbled 14% after the company's second-quarter results missed analysts' estimates on both top and bottom lines. MarketAxess — The electronic trading platform rallied 5.6% after releasing its second-quarter results.

Persons: Johnson, Johnson Covid, Tesla, Abbott, Zions, Estee Lauder, StreetAccount, —, Yun Li, Jesse Pound, Samantha Subin, Michelle Fox Organizations: Netflix, Refinitiv, American Airlines –, American Airlines, IBM, Johnson, Dow Jones, Abbott, Discover Financial, Federal Deposit Insurance, Barclays Locations: Los Angeles , California, China, Freeport

Abbott CEO Robert Ford said the great momentum in device and diagnostics sales during the quarter was due to improving market conditions in healthcare. Rival J&J's (JNJ.N) medical device segment also topped estimates, aided by a recovery in demand for medical procedures. Shares of rival medical device makers Medtronic (MDT.N) and Boston Scientific Corp (BSX.N) rose nearly 3%. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from diabetes device Freestyle Libre, beating analysts' estimates of $4.10 billion. Abbott's adjusted profit of $1.08 per share in the quarter beat analysts' estimates of $1.05.

Persons: Robert Ford, J, Shagun Singh, Abbott, Khushi Mandowara, Pooja Desai Organizations: Abbott Laboratories, RBC Capital Markets, Boston Scientific Corp, U.S, Thomson Locations: Michigan, Bengaluru

☆ Wall St Week Ahead As earnings loom, investors weigh recession resilience
▼ + stars: | 2023-07-07 | by ( David Randall | ) www.reuters.com time to read: +5 min

The financials sector is down 2%, while energy is nearly 9% lower. These unloved sectors are growing attractive to investors increasingly torn over whether a long-feared U.S. recession will ever materialize. Quincy Krosby, chief global strategist for LPL Financial noted a "tug of war" in the market over the likelihood of a recession. The healthcare sector trades at a forward price-to-earnings ratio of 17.6, well below the 20.1 ratio of the broad S&P 500. Yet a continued rally in megacaps will likely stretch their valuations further, prompting some investors to rotate toward healthcare and financials, LPL Financial's Krosby said.

Persons: Goldman Sachs, Quincy Krosby, Sameer Samana, Max Wasserman, Financials, Tom Ognar, Morgan Stanley, John Quealy, Financial's Krosby, David Randall, Megan Davies, Michelle Price, Richard Chang Organizations: YORK, Global, BofA, Commerce Department, LPL Financial, Reserve, Wells, Wells Fargo Investment Institute, FINANCIALS, Miramar Capital, Abbott Laboratories, Allspring Global Investments, LPL Financial Holdings Inc, Trillium Asset Management, Russell, Thomson Locations: U.S, BlackRock, Wells Fargo, megacaps

New rules imposed in February force infant formula makers to invest heavily to re-make, test, certify and re-register their products for China, before potentially conducting new marketing campaigns. “The new standard requires higher product quality as well as stronger manufacturing techniques which are expected to eliminate many small-to-medium-size players,” said Quinn Mai, analyst at Euromonitor International, which estimates China’s infant formula market will fall 12.5% to $21 billion by 2025 due to shrinking demand. China's National Health Commission (NHC) cited infant safety when announcing the latest rules. Celia Ning, director at the nutrition research institute of formula maker Junlebao, said the registration process could "easily" take a year. Another, Fonterra (FCG.NZ), said it was progressing through the re-registration process but that infant formula made up a relatively small part of its China business, with declining birth rates and regulation driving industry consolidation.

Persons: ”, Quinn Mai, Jane Li, Li, Celia Ning, Junlebao, Ning, SAMR, Nestle, Marius Zaharia Organizations: Euromonitor, Health Commission, NHC, State Administration, Market, “, Unicef, Companies, Abbott Laboratories, Reuters, New Zealand's Ministry, Primary Industries, Milk, Global, Nestle, Danone, HK, “ Companies, Thomson Locations: HONG KONG, China, Auckland, “ Beijing, India, U.S, Hong Kong, Beijing, Lincoln

☆ Medical spending is rising. Here’s why that could be bad news for the biggest health-care ETFs
▼ + stars: | 2023-06-15 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +2 min

A warning from UnitedHealth Group executives Wednesday that demand for medical services was rising sent insurance stocks tumbling and, in turn, hit investors who bet on health care. The biggest health-care exchange-traded fund, the $41 billion Health Care Select Sector SPDR Fund (XLV) , lost 1% Wednesday. The $17 billion Vanguard Health Care ETF (VHT) also fell about 1%. XLV 5D mountain The XLV was dragged down by insurance stocks on Wednesday. Some Wall Street analysts said the dramatic sell-off in typically stodgy insurance stocks could prove to be a buying opportunity.

Persons: John Franklin Rex, Rex, that's, Cantor Fitzgerald, Sarah James, — CNBC's Michael Bloom Organizations: UnitedHealth Group, Humana, CVS Health, Health Care, CVS, Devices, Abbott Laboratories

While the overall market awaits a debt ceiling deal, certain stocks are forming notable patterns followed by chart analysts: the bullish golden cross and the dreaded death cross. Meanwhile, a death cross is the exact opposite. Stocks closing in on a death cross pattern include American Express and United Parcel Service. A bullish pattern forms Shares of paint company Sherwin-Williams are forming a bullish golden cross. Shares of shipping giant UPS are also on pace to form a death cross.

Persons: Sherwin, Williams, Refinitiv, Carol Tomé Organizations: CSX, American Express, United Parcel Service, CNBC, Abbott Laboratories, U.S . Food, Drug Administration, Mobile Locations: U.S

We're initiating a position in GE Healthcare (GEHC), buying 325 shares at roughly $79 each. GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions. GE Healthcare is one of the global leaders in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging. GE Healthcare is one of a few companies that offer a full suite of products and solutions to support patients. GEHC YTD mountain GE Healthcare YTD performance Analysts see GE Healthcare growing EPS to $4.33 in 2024, about a 15% increase from this year's outlook.

The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks. Noriega dismissed PediaSure as "just a flavored sugar and milk-based drink that contains vitamins, which is not a cure for shortness." She said also that Abbott "knows from its own studies that its Clinically Proven Claim is false and misleading." PediaSure is part of the Abbott Park, Illinois-based company's pediatric nutritional segment, which also includes Pedialyte and Similac. The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No.

☆ GOP law cut Big Pharma tax rates by 40%, Senate report says
▼ + stars: | 2023-05-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

A Republican law has slashed the average tax rates of big pharmaceutical companies by more than 40% since it was enacted in 2017, Senate Finance Committee Democrats said in a report Thursday. That provision allowed U.S.-based pharmaceutical companies to access lower tax rates on their foreign income, the report said. Pharmaceutical companies report 75% of their taxable income overseas, the report said. The report said the average rate fell to 11.6% in 2019 and 2020, which resulted in billions of dollars in tax savings for pharmaceutical companies. Wyden also obtained similar information about other U.S. pharmaceutical companies, including Abbott Laboratories , Amgen , Bristol Myers Squibb and Merck .

☆ A number of outperforming stocks have bucked macro trends, Jim Cramer says
▼ + stars: | 2023-05-08 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +1 min

Investors should be wary of bearish strategists who opt for a macro view and instead focus on individual companies, CNBC's Jim Cramer said Monday. In a market where idiosyncratic performers are plentiful, following one-size-fits-all macro advice can leave investors confused, Cramer says. Cramer pointed to outsize performers in myriad industries that would have been written off by those same bearish strategists. Investors might expect that industrial and homebuilding stocks would be suffering given the continued rate hikes, Cramer said. But industrial names like General Electric or Cummins have done extremely well, as have housing stalwarts like KB Home and Lennar , Cramer said.

☆ Zimmer Biomet raises annual forecasts on knees and hips unit strength
▼ + stars: | 2023-05-02 | by ( ) www.reuters.com time to read: +2 min

[1/2] The logo of medical implants maker Zimmer Biomet is seen at a plant in Winterthur, Switzerland, November 16, 2018. REUTERS/Moritz HagerMay 2 (Reuters) - Zimmer Biomet Holdings Inc (ZBH.N) raised its annual sales and profit forecasts on Tuesday, banking on strong demand for its knees and hips products amid a sustained recovery in surgical procedures in the United States. Shares of the Indiana-based medical device maker rose 3.72% to $144 before the bell, also buoyed by better-than-expected first-quarter results. Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp (SYK.N) and larger rival Abbott Laboratories (ABT.N), raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. The medical device maker's revenue rose 10% to $1.83 billion in the first quarter, beating analysts' average estimates of $1.70 billion.

Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. The Dow Jones Industrial Average (.DJI) fell 79.62 points, or 0.23%, to 33,897.01; the S&P 500 (.SPX) lost 0.35 points, or 0.01%, at 4,154.52; and the Nasdaq Composite (.IXIC) added 3.81 points, or 0.03%, at 12,157.23. The defensive utilities group (.SPLRCU) gained most among S&P 500 sectors, rising 0.8%. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. The S&P 500 posted 16 new 52-week highs and one new lows; the Nasdaq Composite recorded 59 new highs and 123 new lows.

Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. The defensive utilities group (.SPLRCU) gained most among S&P 500 sectors, rising 0.7%. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. Shares of Western Alliance Bancorp (WAL.N) surged 23% after the company posted stronger-than-expected earnings, helping lift the SPDR S&P Regional Banking ETF (KRE.P) 4%. The S&P 500 posted 15 new 52-week highs and one new low; the Nasdaq Composite recorded 48 new highs and 111 new lows.

Abbott is the second major company to signal a recovery in medical device sales. Medical devices - Abbott's largest segment - clocked an 8.5% rise in sales to $3.90 billion, with $1.2 billion coming from glucose monitoring device Freestyle Libre. I don't think it's a bolus of backlog," Abbott CEO Robert Ford said about the recovery in medical device sales. The stronger outlook for its non-COVID business was the main takeaway as investors had priced in a fall in COVID testing sales, J.P. Morgan analyst Robbie Marcus said in a note. Abbott lowered its outlook for COVID testing sales this year to $1.5 billion from the $2 billion it forecast in January.

Search resuls for: "Abbott Laboratories"

25 mentions found